A Thermo-responsive Biopharmaceutical to Enhance the Tear Production of Lacritin
一种增强泪液分泌的热响应生物药物
基本信息
- 批准号:8448449
- 负责人:
- 金额:$ 14.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-09-30 至 2015-09-29
- 项目状态:已结题
- 来源:
- 关键词:AdhesivesAdverse effectsAffectAmericanBehaviorBiocompatibleBiological ProductsBody TemperatureCharacteristicsDataDevelopmentDiseaseDoseDrainage procedureDropsDrug Delivery SystemsDrug FormulationsDrug vehicleDry Eye SyndromesElastinElderlyEquilibriumEvaluationEyeEyedropsFigs - dietaryFilmFrequenciesGelGenetic EngineeringGlycoproteinsGoalsHeatingHourHumanIn VitroLabelLengthLiquid substanceModelingMolecular WeightNanostructuresOryctolagus cuniculusPeptidesPharmaceutical PreparationsPharmacologic SubstancePhasePhase TransitionPolymersPostmenopauseProcessProductionPropertyProteinsRecombinantsResidenciesRouteScheduleSolutionsTemperatureTimeToxic effectTransition TemperatureTropoelastinViscosityWomanaqueouscombatdesignenvironmental changeeye drynessin vivoinnovationlight scatteringmacromoleculenovelpolypeptidepreventprotein purificationpublic health relevanceresearch studyresidencescaffoldself assemblysmall molecule
项目摘要
Project Summary/Abstract
Ocular pharmaceuticals predominantly use the topical route of administration, which involves a number of
benefits and limitations when compared to systemic drug routes. A major limitation of the ocular topical route is
the rapid loss of drug via tearing and nasolacrimal drainage, requiring the use of frequent dosing and high drug
concentrations that then create formulation difficulties, together with the potential for local and systemic
adverse effects. The proposed innovation is to use the temperature sensitivity of the genetically engineered
smart polymer class of elastin-like polypeptides (ELP) to control ocular clearance. ELPs have unique
properties that promote phase separation, recombinant expression, protein purification, and self-assembly of
nanostructures. ELPs are repeated pentameric peptides, (VPGXG)n, that have characteristic inverse phase
transition temperatures, Tt, above which they phase separate from aqueous solution. By selecting X and the
length n, ELPs of different Tt can be efficiently and precisely biosynthesized. Genetically engineered ELPs are
pharmacologically relevant, being monodisperse, biodegradable, and biocompatible. Lacritin, a new-found,
short glycoprotein promotes tear secretion in dry eye models but must be administered several times a day.
Lacritin will be genetically fused with ELPs of different transition temperatures and molecular weights to
optimize the construct for drug retention. Free, active lacritin is expected to be in equilibrium with the ELP
aggregates, thus extending ocular lacritin residency. ELPs with a transition temperature greater than 37¿C
should clear quickly from the eye; however, ELPs with transition temperature between room temperature
(25¿C) and body temperature (37¿C) are expected to drain slowly. The following specific aims are designed to
serve as a proof of concept of this idea: SA1) Synthesis and in vitro demonstration of lacritin-ELP thermal
sensitivity. Thermally sensitive and insensitive ELPs with and without fluorescent labels will be prepared with
molecular weights ranging from 10 to 50 kD and fused to lacritin. Our milestone will be to produce a thermally
sensitive ELP-lacritin that will have a transition temperature of between 25 and 37¿C, suitable for use in an eye
drop. SA2) Efficacy and tolerability evaluation of lacritin-ELP in in vivo normal rabbit and in vitro
Ussing chamber ocular models. Optimal fusion peptides will be evaluated for residency, ocular tolerability
and lacritin-stimulated tear formation in in vivo normal rabbit models and in in vitro Ussing chamber residency
experiments. Our milestone is to demonstrate that the thermally-sensitive lacritin-ELP is more effective than
the thermally-insensitive product at increasing tear production without significant local or systemic toxicity.
项目摘要/摘要
眼药主要使用局部给药途径,其中涉及多个
与全身药物路线相比,益处和局限性。眼局部途径的主要限制是
通过撕裂和鼻泪排水迅速损失药物,需要使用频繁给药和高药物
然后造成公式困难的浓度,以及局部和系统性的潜力
不利影响。提出的创新是使用基因工程的温度灵敏度
弹性蛋白样多肽(ELP)的智能聚合物类,以控制眼清除。 ELP具有独特性
促进相分离,重组表达,蛋白质纯化和自组装的特性
纳米结构。 ELP是重复具有特征逆相的五聚肽(VPGXG)N
过渡温度,TT,上面它们与水溶液分离。通过选择X和
长度为n,不同TT的ELP可以有效,精确地化为生物合成。基因工程ELP是
在药理上相关,是单分散,可生物降解和生物相容性的。曲息蛋白,新发现,
短糖蛋白在干眼模型中促进撕裂分泌,但每天必须几次给药。
流质蛋白通常与不同的过渡温度和分子量的ELP融合到
优化用于保留药物的结构。预计游离活性乳葡萄蛋白将与ELP保持平衡
聚集体,因此扩展了眼绿蛋白的住所。过渡温度大于37 c的ELP
应该从眼睛迅速清楚;但是,在室温之间具有过渡温度的ELP
(25¿C)和体温(37°C)预计会缓慢排水。以下特定目标旨在
作为这一想法的概念证明:SA1)合成和体外演示曲息蛋白-ELP热形成
灵敏度。带有和不具有荧光标签的热敏感和不敏感的ELP将使用
分子量范围从10到50 kD,融合到透眼素。我们的里程碑将是热产生
敏感的ELP曲息蛋白的过渡温度在25至37°C之间,适用于眼睛
降低。 SA2)在体内正常兔子和体外的基质素-ELP的功效和耐受性评估
使用室内眼模型。最佳的融合宠物将评估居住,眼部耐受性
在体内正常兔模型和体外用途的室内住宅中,在体内刺激的泪液形成和流质蛋白刺激
实验。我们的里程碑是证明热敏感的曲息蛋白-ELP比
没有明显的局部或全身毒性的泪液产生时增加的热敏感产物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sandeep Samudre其他文献
Sandeep Samudre的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
基因与家庭不利环境影响儿童反社会行为的表观遗传机制:一项追踪研究
- 批准号:
- 批准年份:2020
- 资助金额:58 万元
- 项目类别:面上项目
不利地质结构对地下洞室群围岩地震响应影响研究
- 批准号:51009131
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
列车制动力对铁路桥梁的作用机理及最不利影响的研究
- 批准号:50178004
- 批准年份:2001
- 资助金额:23.0 万元
- 项目类别:面上项目
相似海外基金
Retinal-adhesive thermoresponsive gel for AAV-mediated gene delivery to the outer retina
用于将 AAV 介导的基因传递至外视网膜的视网膜粘附热敏凝胶
- 批准号:
10709508 - 财政年份:2022
- 资助金额:
$ 14.64万 - 项目类别:
Retinal-adhesive thermoresponsive gel for AAV-mediated gene delivery to the outer retina
用于将 AAV 介导的基因传递至外视网膜的视网膜粘附热敏凝胶
- 批准号:
10453146 - 财政年份:2022
- 资助金额:
$ 14.64万 - 项目类别:
BIOMATERIALS FOR STEM CELL-DERIVED BETA CELL TRANSPLANTATION
用于干细胞衍生的 β 细胞移植的生物材料
- 批准号:
10684716 - 财政年份:2021
- 资助金额:
$ 14.64万 - 项目类别:
Targeting the Genus Leishmania with Small Molecules
用小分子靶向利什曼原虫属
- 批准号:
10377374 - 财政年份:2021
- 资助金额:
$ 14.64万 - 项目类别:
BIOMATERIALS FOR STEM CELL-DERIVED BETA CELL TRANSPLANTATION
用于干细胞衍生的 β 细胞移植的生物材料
- 批准号:
10306891 - 财政年份:2021
- 资助金额:
$ 14.64万 - 项目类别: